文档介绍：LMR值对R-CHOP方案初治滤泡性淋巴瘤患者的效果及预后的影响
[摘要] 目的 探討LMR值对R-CHOP方案初治滤泡性淋巴瘤患者的效果及预后的影响。 方法 选择2013年1月~2016年1月在我院诊断治疗的初始滤泡淋巴瘤患ate risk, both significantly higher than that of the high-risk group. The difference was significant(P<). The three-year progression-free survival rate in the low-risk group was significantly higher than that in the high-risk group. The 2-year survival rate and the 3rd year survival rate in the low- risk group were significantly higher than those of the high-risk group, and the difference was statistically significant (P<). The average survival rate of patients with LMR ≥ was significantly higher than that of patients with <,and the three-year progression-free survival rate of patients with LMR ≥ was significantly higher than that of patients with <. The second-year survival rate and the third-year survival rate of patients with LMR ≥ were significantly higher than those with<, and the difference was statistically significant(P<). Conclusion Patients with newly diagnosed follicular lymphoma with LMR ≥ have better R-CHOP regimen and a higher 3-year progression-free survival rate. [Key words] R-CHOP chemotherapy regimen; Initial treatment of follicular lymphoma; LMR value; Prognosis
滤泡性淋巴瘤在全世界占非霍奇金淋巴瘤(Non-Hodgkin lymphoma,NHL)的22%。滤泡性淋巴瘤最常见的表现是无痛性淋巴结肿大,典型表现为多部位淋巴组织侵犯,有时可触及滑车上淋巴结肿大。血液病理学专家评估一个合适的活检足以作出滤泡性淋巴瘤的诊断。滤泡性淋巴瘤是对化疗和放疗最有效的恶性肿瘤之一[1]。外周血淋巴细胞(absolute lymphocyte count,ALC)/单核细胞(absolute monocyte count,AMC)即淋巴细胞单核细胞比值(lymphocyte to monocyte ratio,LMR)可以反映机体免疫状态,在一定程度上可以用于判断患者预后[2]。有研究显示,LMR是霍奇金淋巴瘤患者预后不良的独立影响因素[3]。R-CHOP化疗方案是当今被证实为最有效的治疗淋巴瘤的方案之一,是临床常用的化疗方案[4]。本文旨在分析R-CHOP化疗方案对初治滤泡性淋巴瘤患者LMR值的影响以及治疗后患者预后情况,以期为临床提供参考,现报道如下。
1 资料与方法
一般资料
选择2013年1月~2016年1月在我院诊断治疗的初始滤泡淋巴瘤患者88例为研究对象。纳入标准:经病理活检确诊为滤泡性淋巴瘤,CD20阳性,采用R-CHOP化疗方案,临床资料完整。排除标准:其他类型淋巴瘤,非初治,其他方式治疗,预计生存期<3个月,对治疗方案严重不耐受,未进行规范化治疗者。本研究经过医院医学伦理委员会同意。88例患者中,男49例,女39例,年龄21~68岁,平均(±)岁;其中53例患者年龄≤60周岁;病理分级:1级28例,2级32例,3级28例;治疗前22例患者Hb245 U/L;28例患者